Advertisement

Search Results

Advertisement



Your search for Tracy Batchelor, MD matches 12 pages

Showing 1 - 12


cns cancers
geriatric oncology

Optimizing Treatment for Elderly Patients With Glioblastoma

In 2005, Stupp and colleagues published their landmark paper demonstrating in a randomized phase III trial that the addition of temozolomide to radiation increased overall survival in patients with newly diagnosed glioblastoma. Notably, patients over age 70 years were excluded from this study.1...

cns cancers

Radiotherapy vs Temozolomide in Low-Grade Glioma: The Importance of Molecular Classification

The optimal treatment strategy for low-grade glioma has yet to be established, and practice patterns vary in regard to the timing of treatment, as well as the chosen treatment modality. It was against this backdrop, at a time when the benefits of radiation and chemotherapy remained uncertain but ...

cns cancers

Understanding and Managing Pseudoprogression in Glioblastoma Patients

Pearls in Neuro-oncology is guest edited by Tracy Batchelor, MD, Director, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, and Professor of Neurology, Harvard Medical School, Boston. The series is intended to provide the practicing oncologist with guidance in managing...

cns cancers

Management of Brain Metastases

Pearls in Neuro-oncology is guest edited by Tracy Batchelor, MD, Director, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, and Professor of Neurology, Harvard Medical School, Boston. The series is intended to provide the practicing oncologist with guidance in managing...

cns cancers

Management of Anaplastic Oligodendroglial Tumors 

Pearls in Neuro-oncology is guest edited by Tracy Batchelor, MD, Director, Division of Neuro-Oncology, Massachusetts General Hospital Cancer Center, and Professor of Neurology, Harvard Medical School, Boston. The series is intended to provide the practicing oncologist with guidance in managing...

cns cancers

No Progression-Free Survival Difference for Cediranib or Cediranib/Lomustine vs Lomustine in Recurrent Glioblastoma

In a phase III study (REGAL trial) reported in the Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of the Massachusetts General Hospital Cancer Center, and colleagues compared oral monotherapy with the investigational pan–vascular endothelial growth factor (VEGF) receptor tyrosine kinase ...

cns cancers

Surgical Resection of Newly Diagnosed Glioblastoma: What Is the Standard of Care?

The neurosurgeon is often the gateway provider when patients present with what on magnetic resonance imaging (MRI) appears to be a new glioblastoma. Because histology-based diagnosis is a prerequisite for initiating standard therapy with radiation and chemotherapy, the first question that the...

cns cancers

Treating Brain Cancer in 2014

While primary malignant brain tumors account for only 2% of all adult cancers, these deadly neoplasms cause severe cancer-related disability; the 5-year survival rates for brain tumors rank third lowest among all cancers, with those for pancreas and lung cancers being first and second lowest,...

cns cancers

Clinical Trials Actively Recruiting Patients With Glioblastoma

The information contained in this Clinical Trials Resource Guide includes actively recruiting clinical studies for patients with newly diagnosed or recurrent glioblastoma multiforme. The studies include pilot, phase I, I/II, III, and observational trials investigating chemoradiation therapy;...

cns cancers

Imaging Studies May Predict Tumor Response to Antiangiogenic Drugs

Advanced imaging techniques may be able to distinguish which patients' tumors will respond to treatment with antiangiogenic drugs and which will not. In a report published online in PNAS, researchers studied patients with newly diagnosed glioblastoma who were treated with the antiangiogenic agent...

cns cancers

No Progression-Free Survival Difference for Cediranib or Cediranib/Lomustine vs Lomustine in Recurrent Glioblastoma

In a phase III study (REGAL trial) reported in Journal of Clinical Oncology, Tracy T. Batchelor, MD, MPH, of Massachusetts General Hospital, and colleagues compared oral monotherapy with the pan-VEGF tyrosine kinase inhibitor cediranib and the combination of cediranib plus lomustine (CeeNu) vs...

cns cancers

New MRI Technique Reveals Brain Tumor Response to Antiangiogenesis Therapy

A new way of analyzing data acquired in magnetic resonance imaging (MRI) appears to be able to identify whether or not tumors are responding to antiangiogenesis therapy, which may help physicians determine the most appropriate treatments for patients. In a report published online in Nature...

Advertisement

Advertisement



;
Advertisement